ATAGABALIN

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H19NO2
Molecular Weight	185.2634
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C

InChI

InChIKey=IUVMAUQEZFTTFB-YUMQZZPRSA-N

InChI=1S/C10H19NO2/c1-7-3-10(6-11,4-8(7)2)5-9(12)13/h7-8H,3-6,11H2,1-2H3,(H,12,13)/t7-,8-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT00569972 | https://www.ncbi.nlm.nih.gov/pubmed/21664606

Atagabalin, also known as PD-0200390, was studied in phase II clinical trials in patients with primary insomnia, but this trial was discontinued because of the unsatisfied results. Atagabalin is a ligand to the α(2)δ subunit of voltage-sensitive calcium channels

Originator

Approval Year

Patents

Sample Use Guides

In Vivo Use Guide

Capsules, 15 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days

Route of Administration: Oral

Name

Type

Language

ATAGABALIN

Official Name

English

PD-0200390

Preferred Name

English

Atagabalin [WHO-DD]

Common Name

English

CYCLOPENTANEACETIC ACID, 1-(AMINOMETHYL)-3,4-DIMETHYL-, (3S,4S)-

Common Name

English

atagabalin [INN]

Common Name

English

[(3S,4S)-1-(Aminomethyl)-3,4-dimethylcyclopentyl]acetic acid

Systematic Name

English

ATAGABALIN [USAN]

Common Name

English

PD0200390

Code

English

Code System Code Type Description

PUBCHEM

9794485